title: Lobeline Effects on Cognitive Performance in Adult ADHD.
abstract: In preclinical studies, lobeline inhibited hyperactivity induced by nicotine and amphetamine, and improved performance and learning in studies utilizing radial-arm maze and spatial-discrimination water maze. This laboratory proof-of-concept study investigated lobeline as a treatment for ADHD symptoms in adults (31.11 ± 7.08 years).
  
  
  
  Using cognitive tasks and self-report measures, the effects of lobeline (0, 7.5, 15, or 30 mg, s.l.) and methylphenidate (0, 15, or 30 mg, p.o.) were assessed in nine volunteers with ADHD.
  
  
  
  Evidence suggested that lobeline could modestly improve working memory in adults with ADHD, but no significant improvement in attention was observed. Lobeline administration was associated with mild adverse side effects (nausea).
  
  
  
  Further investigation of lobeline on working memory may be warranted.
authors: 1 University of Kentucky, Lexington, KY, USA.
authors: Catherine A
authors: CA
authors: Martin
authors: 1 University of Kentucky, Lexington, KY, USA.
authors: Paul A
authors: PA
authors: Nuzzo
authors: 1 University of Kentucky, Lexington, KY, USA.
authors: John D
authors: JD
authors: Ranseen
authors: 2 Yaupon Therapeutics, Malvern, PA, USA.
authors: Mark S
authors: MS
authors: Kleven
authors: 1 University of Kentucky, Lexington, KY, USA.
authors: Greg
authors: G
authors: Guenthner
authors: 1 University of Kentucky, Lexington, KY, USA.
authors: Yolanda
authors: Y
authors: Williams
authors: 1 University of Kentucky, Lexington, KY, USA.
authors: Sharon L
authors: SL
authors: Walsh
authors: 1 University of Kentucky, Lexington, KY, USA.
authors: Linda P
authors: LP
authors: Dwoskin
mesh_terms: D000328:Adult; D001288:Attention / Q000187:drug effects / Q000502:physiology; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007175:Impulsive Behavior / Q000187:drug effects*; D008120:Lobeline / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects*; D008774:Methylphenidate / Q000008:administration & dosage* / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D018722:Nicotinic Agonists; D008774:Methylphenidate; D008120:Lobeline
keywords: ADHD; lobeline; methylphenidate
references: Am J Psychiatry. 2001 Jul;158(7):1067-74
references: 11431228
references: J Learn Disabil. 1998 Nov-Dec;31(6):533-44
references: 9813951
references: Arch Int Pharmacodyn Ther. 1969 Dec;182(2):370-5
references: 5371188
references: Pharmacol Biochem Behav. 2003 Jan;74(2):279-86
references: 12479946
references: Life Sci. 2006 Aug 1;79(10):981-90
references: 16765386
references: Neurosci Biobehav Rev. 2003 Nov;27(7):593-604
references: 14624804
references: Drug Alcohol Depend. 2007 Jul 10;89(2-3):282-91
references: 17368966
references: J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):74-85.e2
references: 22176941
references: Behav Brain Funct. 2005 Apr 22;1(1):2
references: 15916700
references: Am J Psychiatry. 2006 Apr;163(4):716-23
references: 16585449
references: Pharmacol Biochem Behav. 2003 Aug;76(1):133-9
references: 13679226
references: J Pharmacol Exp Ther. 2001 Jul;298(1):172-9
references: 11408539
references: Ann Pharmacother. 2004 Jan;38(1):86-90
references: 14742801
references: Psychopharmacology (Berl). 1991;103(4):436-42
references: 2062984
references: CMAJ. 2005 Dec 6;173(12):1447
references: 16330634
references: Biochem Pharmacol. 2002 Jan 15;63(2):89-98
references: 11841781
references: Biol Psychiatry. 2003 Dec 15;54(12):1465-8
references: 14675812
references: Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58
references: 5554941
references: Am J Psychiatry. 1998 May;155(5):693-5
references: 9585725
references: Neuropharmacology. 2000 Oct;39(13):2654-62
references: 11044735
references: J Am Acad Child Adolesc Psychiatry. 2006 Apr;45(4):415-21
references: 16601646
references: Arch Pediatr Adolesc Med. 2011 Aug;165(8):729-35
references: 21810634
references: J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):978-90
references: 21961773
references: J Pharmacol Exp Ther. 2001 Mar;296(3):1023-34
references: 11181937
references: Physiol Behav. 2009 Jun 22;97(3-4):503-6
references: 19268674
references: J Pharmacol Exp Ther. 1997 Mar;280(3):1432-44
references: 9067333
references: Psychopharmacology (Berl). 1992;108(4):417-31
references: 1357713
references: Cochrane Database Syst Rev. 2000;(2):CD000124
references: 10796490
references: Arch Clin Neuropsychol. 2005 Aug;20(6):727-44
references: 15953706
references: Biol Psychiatry. 2005 Jun 1;57(11):1377-84
references: 15950011
references: J Am Acad Child Adolesc Psychiatry. 2011 Feb;50(2):171-9
references: 21241954
references: J Neurosci. 2001 Jan 15;21(2):RC121
references: 11160455
references: Pharmacol Biochem Behav. 1993 Jul;45(3):571-6
references: 8332618